Development of nucleoside therapeutics with anti-viral or antitumor characteristics
Advanced Magnetics will sponsor research over 3 years (7/98)
Advanced Tissue Sciences Inc.
The Massachusetts Institute of Technology and Children¿s Hospital, Boston
License
Technology for growth of vascularized human tissues or organs on three-dimensional biocompatible, biodegradable and nonbiodegradable polymer scaffolds in vivo
Advanced Tissue licensed rights to 3 patents for use in broad range of tissues and organs (6/98)
Advanced Viral Research Corp. (OTC Bulletin Board:ADVR)
National Cancer Institute of the National Institutes of Health [Howard Young]
Cooperative Research and Development Agreement/ Material Transfer Agreement (CRADA/ MTA)
Research on antitumor activity and anti-inflammatory activity of Reticulose (a peptide nucleic acid product)
Original agreement, from 3/97, was extended for 1 year to 3/99 (3/98)
Affymetrix Inc.
Howard Hughes Medical Institute
Supply agreement
Subscription-based academic Easy-Access supply agreement for custom and standard GeneChip expression monitoring probe arrays
Howard Hughes investigators get broad access to GeneChip probe arrays, instrumentation and software to use in fundamental medical research; 2.5-year agreement; Affymetrix gets subscription fees and fixed per-chip fees with a volume commitment from Howard Hughes Institute (4/98)
Allergene Inc.*
University of Arizona [Jack Marchalonis; Ronald Watson]
License
T-cell receptor peptide (ALG889) that can reverse some immune system abnormalities found in HIV infection and other immune diseases
Allergene acquired rights to peptide and expects to begin Phase I/II trials in AIDS by end of year (5/98)
American Biogenetic Sciences Inc.
The National Institutes of Health (NIH)
Research collaboration
Evaluation of American Biogenetic¿s drug ABS-103 (derivative of epilepsy drug valproate) as therapy for epilepsy
Preclinical research; use of NIH¿s database to compare efficacy and toxicity of ABS-103 to that of other existing and experimental epilepsy therapies (8/98)
American Biogenetic Sciences Inc.
The University of Maryland [Neil Constantine]
Research collaboration
Development of assay that detects presence of antibodies to human herpes virus type 8
State of Maryland, through Maryland Industrial Partnerships agreement, will match company¿s investment in project (8/98)
AMRAD Corp. (Australia)
University of Tasmania, Menzies Centre for Population Health Research [Terry Dwyer]
Research collaboration
Establishment of genetic epidemiology unit to conduct research on Tasmanian families for disease genes; initial targets include osteoporosis, multiple sclerosis and endometriosis
Tasmania has an isolated, inbred population with existence of multigenerational historical records; AMRAD will provide A$2.5M (US$1.5M) over 5 years to set up unit; AMRAD has option to commercialize any drugs or technology that result; Menzies Centre gets royalties (1/98)
AntexBiologics (OTC Bulletin Board:ANTX)
The National Institutes of Health
License
Development of bacterial and fungal carbohydrate receptor technologies for use in diagnostics and therapeutics
Antex licensed rights to 7 patents (10/98)
ArQule Inc.
Beth Israel Deaconess Medical Center [Michael Chorev]
Sponsored research agreement
Therapeutics for treating bone and mineral diseases, initially osteoporosis (molecular nature of compounds ND)
ArQule will assess and select compounds from its Mapping Array program using Beth Israel¿s assays for biological actions on bone; active leads will be optimized via ArQule¿s Directed Array program; ArQule will sponsor research and gets option on exclusive license to any new drug candidates (5/98)
Aurora Biosciences Corp.
The University of California, San Diego [Roger Tsien]
License
Specific covalent labeling of recombinant protein molecules inside living cells (FLASH system; involves fluorescent label)
Aurora gets exclusive license (7/98)
AVI Biopharma Inc.
The University of Nebraska Medical School
License
Telomere mimics (synthetic oligonucleotides) for treating cancer and other diseases; also, ultrasound contrast agent (microbubbles coated with albumin) to be used for targeted drug delivery
AVI Biopharma gets exclusive licenses to 9 issued patents, 6 pending patent applications and 1 provisional patent application (8/98)
Bio-Technology General Corp.
Duke University
License
Polyethylene glycol (PEG) conjugates of recombinant uricase to treat gout and risk of kidney failure
Bio-Technology General licensed exclusive worldwide rights to technology from Duke and Mountain View Pharmaceuticals Inc.; the latter will transfer PEG technology to Bio-Technology General, which will produce PEG-uricase conjugates, conduct clinical trials and commercialize product; partial funding provided by the Israel-U.S. Binational Industrial Research and Development Foundation (8/98)
Biora AB (Sweden)
University of Texas Health Science Center [David Cochran] and University of Ulm (Germany) [Axel Spahr]
Two research collaborations
Identification of new indications for Emdogain (protein-based gel for periodontal flap surgery); also, development of regenerative technologies for periodontal treatment and oral surgery
Each collaboration is for 3 years; further details ND (6/98)
Biota Holdings Ltd. (ASX:BTA; Australia)
The Howard Florey Institute of Experimental Physiology and Medicine (Australia) [Frederick Mendelsohn]
License; research collaboration
Development of neuroactive compound (not described) that affects short-term memory as treatment for Alzheimer¿s disease and other memoryrelated disorders
Biota will assist institute in characterizing compound; Biota is responsible for commercializing research and will identify pharmaceutical partners for development and commercialization (2/98)
Biota Holdings Ltd. (ASX:BTA; Australia)
La Trobe University (Australia) [Les Deady]
Extension of research collaboration
Chemical anticancer compounds (mixed topoisomerase inhibitors) for treating colon cancer and other solid tumors; initiation of preclinical development
Agreement dates from 4/97; Biota will extend its research support for another 12 months; university will provide scaled up chemical synthesis of selected drug leads for animal studies (1/98)
Biovector Therapeutics SA* (France)
National Institutes of Health (NIH) [Alain Thierry]
License
DLS technology for drug delivery (including therapeutic proteins); delivers DNA via subcutaneous or intravenous injection
Thierry, inventor of the technology, joined Biovector as director of gene therapy and delivery; NIH gets milestones and royalties on any products (5/98)
Boston Life Sciences Inc.
Harvard University [Harvey Cantor]
License
BCLx-gamma gene; controls apoptosis in T cells
Boston Life gets rights to gene; further details ND (3/98)
Cadus Pharmaceutical Corp.
Massachusetts Institute of Technology [Ian Hunter]
License; sponsored research agreement
Development of next-generation biochip screening system; disposable CD-sized screening tool that will accommodate 100,000 cell-based assays on a single chip
Project combines Cadus¿ yeast-based drug discovery assays with Hunter¿s expertise in microrobotics (living machines) (1/98)
Cell Therapeutics Inc.
City of Hope National Medical Center
Joint venture
Development of drugs that block oxygen-carrying molecules (including reactive oxidized lipids) that attack pancreas and cause insulin resistance and other complications of diabetes
Joint venture is expansion of 2-year collaboration between two parties; Cell Therapeutics will fund 1st 2 years of joint venture and provide technology in oxidized lipid chemistry; City of Hope contributes its rights to human leukocyte 12-lipoxygenase (generates oxidized lipids); Cell Therapeutics holds 70% of joint venture, City of Hope holds 30%; financial terms ND (1/98)
Cell Therapeutics Inc.
The University of Texas M.D. Anderson Cancer Center [Sidney Wallace; Chun Li]
License
Polyglutamic acid paclitaxel (water-soluble version of anticancer agent paclitaxel)
Cell Therapeutics licensed rights to product; further details ND (7/98)
Cel-Sci Corp.
Naval Research Institute of the U.S. Navy
Cooperative Research and Development Agreement (CRADA)
Joint development of malaria vaccine via CelSci¿s ligand epitope antigen presentation technology (LEAPS; combines T-cell binding ligand with disease-associated peptide antigens)
CRADA is extension of 8/96 research agreement (7/98)
Celsion Corp. (OTC Bulletin Board:CELN)
Duke University Medical Center [Mark Dewhirst]
Sponsored research agreement
Use of Celsion¿s thermo-therapy system (heat-activated, lipid-based encapsulates) as activating mechanism for targeted drug delivery, gene therapy and anti-angiogenesis systems
Celsion gets exclusive right to negotiate worldwide licenses to technology developed during collaboration (6/98)
Chiron Diagnostics (unit of Chiron Corp.)
Stanford University (Medical Informatics)
Strategic partnership
Joint R&D program to develop clinical decision support systems for health care enterprises; based on Stanford¿s EON software architecture
Multi-year agreement; Chiron gets exclusive license to software architecture; specific terms ND (1/98)
Cobequid Life Sciences Inc. (VSE:KQR; Canada)
The Loeb Research Institute of Ottawa Hospital (Canada) [Heather Davis]
Sponsored research agreement
Continued development of DNA vaccines for 2 major emerging diseases of farmed salmon
ND (6/98)
CoCensys Inc.
Massachusetts General Hospital
License
Use of neuroactive steroids (epalons; including ganaxolone) and other gamma amino butyric acid (GABA) receptor modulators for treating migraine
CoCensys gets exclusive worldwide rights to patent-pending technology; further details ND (1/98)
Corixa Corp.
Washington University, St. Louis [Timothy Fleming; Mark Watson]
License
Human mammaglobin (expressed specifically in adult mammary gland) as marker for breast cancer detection
Corixa gets exclusive option on worldwide diagnostic rights (it previously acquired rights to gene and gene products for use tumor vaccines) (4/98)
Corixa Corp.
Massachusetts Institute of Technology'
License
Wilm¿s tumor gene, over-expression of which is 'seen in many leukemia patients
Corixa obtained exclusive 'rights to gene; further terms ND worldwide license to therapeutic (12/98)
Cortex Pharmaceuticals Inc.
University of California, Irvine [Gary Lynch]
License
Broad patent on use of any AMPA receptor-modulating compound (which increases synaptic transmission) for treating schizophrenia
Cortex gets rights to patent that broadens scope of its potential products (5/98)
Creative BioMolecules Inc.
The Miami Project to Cure Paralysis (the University of Miami School of Medicine)
Research collaboration
Use of Creative Bio-Molecule¿s morphogenic proteins (including OP-1) as therapies to enhance recovery after injury or damage to brain or spinal cord
2-year collaboration; details ND (9/98)
CV Therapeutics Inc.
The Cleveland Clinic Foundation [Eric Topol]
Research collaboration
Preclinical testing of certain of CV¿s small-molecule cell cycle inhibitors (including CVT-313) to reduce occurrence of restenosis after angioplasty due to excessive proliferation of vascular cells
Parties will evaluate use of cell cycle inhibitors in combination with drug delivery catheters and as coatings on endoluminal stents; further details ND (2/98)
Cyanotech Corp.
The Scripps Research Institute
License; production
Production of Scripps¿ genetically engineered aldolase catalytic antibody 38C2 in microalgae (for synthesis of certain anti-cancer compounds and other applications)
Cyanotech licensed the technology to produce the antibody via its 2nd-generation algae cultivation technology PhytoMax; Scripps will provide genetically engineered live microalgae containing aldolase protein to Cyanotech (4/98)
Cyclacel Ltd.* (Scotland)
Centre National de Recherche Scientifique (CNRS; France) [Alain Prochiantz]
License
Penetratin (16 amino acid peptide that acts as cytoplasmic and nuclear transporter); Cyclacel will initially use peptide in conjunction with its Pimetic drug candidates (cell cycle control peptide mimics)
Cyclacel gets exclusive worldwide rights to product for use in cancer (co-exclusive for cancers of central nervous system), autoimmune, cardiovascular, dermatologic and inflammatory diseases; CNRS gets upfront fee, milestones and royalties (7/98)
Cypros Pharmaceutical Corp.
University of Rhode Island
License
Compounds that selectively raise levels of adenosine (a naturally occurring cytoprotective agent) in ischemic tissue
Cypros gets exclusive license to recently patented series of compounds; further details ND (2/98)
Cytoclonal Pharmaceutics Inc.
The University of California, Los Angeles [Richard Pietras]
License
Breast cancer peptide inhibitors (target estrogen receptors)
Cytoclonal gets exclusive worldwide rights; further details ND (8/98)
Cytoclonal Pharmaceutics Inc.
Montana State University
License
Fungus that produces telomerase, a way to produce it outside the human body through microbial fermentation
Exclusive license to the fungus; further details ND (12/98)
Cytotherapeutics Inc.
The Scripps Research Institute [Nora Sarvetnick]
License
Technology to help identify and isolate pancreatic stem/ progenitor cells
Exclusive worldwide license; further details ND (12/98)
Dendreon Corp.*
The Ludwig Institute for Cancer Research
License
Use of Ludwig Institute¿s human tumor antigen NY-ESO-1 in Dendreon¿s dendritic cell immunotherapy; initial targets are prostate cancer and multiple myeloma
ND (8/98)
Desmos Inc.*
The University of California Los Angeles
Extension of matrix research collaboration
Use of extracellular protein laminin-5 as substrate for growth of human pancreatic islet cells (insulin-producing cells to transplant into diabetics)
Desmos will continue to fund research; further details ND (6/98)
Diacrin Inc.
Massachusetts General Hospital [Denise Faustman]
License
Immune system masking technology for long-term acceptance of transplants; involves attachment of antibody molecule to surface of donor cell; focus on treatment of porcine brain cells prior to transplantation into patients with Parkinson¿s disease, Huntington¿s disease and focal epilepsy
Diacrin gets exclusive license; further details ND (7/98)
diaDexus LLC (joint venture between Incyte Pharmaceuticals Inc. and SmithKline Beecham plc; NYSE:SBH)
Cancer Research Campaign Technology Ltd. (U.K.) [Ron Laskey; Nick Coleman; Gareth Williams]
License
Cervical cancer screening technology (details ND)
diaDexus gets exclusive worldwide license to technology, which it will develop and commercialize; terms ND (9/98)
Digene Corp.
McGill University and International Center for Genetic Engineering and Biotechnology (Italy)
License
Rights to p53arg gene, a genetic marker for cervical cancer risk.
Digene paid Mcgill upfront fee for worldwide rights in all appications, and may make milestone and royalty payments, depending on progress (12/98)
Digital Gene Technologies Inc.*
Indiana University School of Medicine [Ting-Kai Li; Lucinda Carr]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to identify mRNAs that are differentially expressed in rats carrying natural genetic variants for alcohol preference (model for alcoholism)
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (6/98)
Digital Gene Technologies Inc.*
The Jackson Laboratory [Wayne Frankel; Gregory Cox]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to study gene expression in mice carrying natural genetic variants (nmd and Mnm genes) that either enhance or suppress degeneration of motor neurons (model for amyotrophic lateral sclerosis)
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (8/98)
Digital Gene Technologies Inc.*
Polish Academy of Sciences [Ryszard Przewlocki]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to study effect of morphine on brain gene expression and to identify genes for addiction
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (7/98)
Digital Gene Technologies Inc.*
The Salk Institute for Biological Sciences [Inder Verma]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to study molecular basis of oncogenesis; identification of genes regulated by BRCA1 (functions as tumor suppressor)
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (8/98)
Digital Gene Technologies Inc.*
The Salk Institute for Biological Sciences [Carrolee Barlow]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to identify differentially expressed genes in mouse model system for ataxiatelangiectasia (Louis Bar syndrome)
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (9/98)
Digital Gene Technologies Inc.*
The Scripps Research Institute [Peter Vogt; Shu-Ling Fu]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to identify and isolate genes that are differentially expressed in chicken cells transformed by jun oncogene
This is 1st project in company¿s program of academic research collaborations using its patented TOGA technology; institution gets fee-free access to technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenues (4/98)
Digital Gene Technologies Inc.*
The Scripps Research Institute [Francis Chisari]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to identify cytokine-induced antiviral proteins that cells infected with virus use to destroy virus internally; focus on chronic hepatitis B virus infection
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (9/98)
Digital Gene Technologies Inc.*
The Scripps Research Institute [Michael Oldstone]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to explore effects of persistent viral infection on brain function
Institute gets access to TOGA to identify CNS genes implicated in mouse brain dysfunction; Digital Gene retains commercial rights; institute gets share of net revenue from products (12/98)
Digital Gene Technologies Inc.
State University of New York, Stony Brook [Simon Halegoua]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to determine full array of genes that regulate the neural actions of growth factors and cytokines
This is 2nd project in program of academic research collaborations; if any products commercialized, academic institution gets share of net revenues (4/98)
Digital Gene Technologies Inc.*
University of Illinois at Chicago [Douglas Feinstein]
Research collaboration
Use of Digital Gene¿s TOGA technology (total gene expression analysis) to isolate genes whose expression will block inflammatory responses of the brain to neuropathies (dementia, Alzheimer¿s disease), infections and diseases
Institution gets fee-free access to TOGA technology; Digital Gene reserves rights to commercial applications of discoveries; institution gets share of net revenue from commercialized products (6/98)
Diversa Corp.
National Autonomous University of Mexico (UNAM)
Research collaboration
Genome research on organisms collected from diverse sites in Mexico to identify novel compounds
Three-year agreement under which Diversa will receive samples collected by UNAM.; Diversa will provide training and equipment, and pay UNAM royalties on resulting products (11/98)
EntreMed Inc.
The National Cancer Institute (NCI) of the National Institutes of Health [James Pluda]
Cooperative Research and Development Agreement (CRADA)
Research to advance studies on endostatin (naturally occurring fragment of collagen XVIII; angiogenesis inhibitor)
This CRADA follows a letter of intent signed in 8/97; 5-year agreement; Entremed will supply human endostatin protein to NCI for specific preclinical pharmacology, toxicology and clinical studies (9/98)
Enzo Biochem Inc.
Hadassah University Hospital (Israel)
Research collaboration
Preclinical analysis of various therapeutics via Enzo¿s immune modulation technologies, including oral tolerization
ND (4/98)
EnzyMed Inc.*
University of Iowa
Research collaboration
Testing of chemical compounds generated via EnzyMed¿s Bioactiv technology for activity against/ affinity for biological targets identified by university scientists
5-year agreement; if any targets lead to marketed drugs, University of Iowa shares in revenues; further details ND (5/98)
Eos Biotechnology Inc.*
The Peter MacCallum Cancer Institute (Australia) [Deon Venter]
Research collaboration
Use of Eos¿ gene expression profiling and bioinformatics capabilities to identify genes with diagnostic, prognostic and therapeutic potential in breast and colorectal cancer
Parties will combine Eos¿ technology with the Institute¿s access to clinical samples and tissue archives as well as molecular pathology (9/98)
GeneMedicine Inc.
University of Texas Southwestern Medical Center at Dallas [Stephen Johnston; Akira Takashima]
Research collaboration
Development of technology for targeting and manipulating dendritic cells, which will be used in genetic vaccines for cancer and infectious diseases
GeneMedicine gets option for exclusive license to any discoveries or inventions; further details ND (5/98)
Genetix Pharmaceuticals Inc.*
Dana-Farber Cancer Institute [Joseph Sodroski]
License
Use of lentiviruses as gene therapy vectors
Genetix gets exclusive worldwide license to issued patent and subsequent patent applications (2/98)
Genome Therapeutics Corp.
The Massachusetts General Hospital [Mason Freeman] and Tufts University [Ernst Schaefer]
Research collaboration
Identification and characterization of gene that causes monogenic HDL deficiency (low levels of high-density lipoproteins in blood; causes premature heart disease)
Massachusetts General and Tufts will collect and analyze DNA samples and histories from an extensive multigenerational family to facilitate cloning of target gene via Genome Therapeutics¿ sequencing and gene identification capabilities; Genome Therapeutics gets exclusive license to commercialize any products (1/98)
Genome Therapeutics Corp.
Princeton University [Thomas Shenk]
License
Genes regulated by p53 tumor suppressor gene
Genome Therapeutics gets exclusive license and retains right to sublicense or partner its oncology program; Princeton gets license fee and royalties (7/98)
Genta Inc.
The National Cancer Institute of the National Institutes of Health
Cooperative Research and Development Agreement (CRADA)
Development of Genta¿s antisense compound G3139 as anticancer agent; G3139 targets BCL-2 gene (whose overexpression inhibits apoptosis)
Parties signed letter of intent to form a CRADA, under which they will collaborate in conducting clinical trials on G3139 (6/98)
Genzyme Corp.
St. Elizabeth¿s Medical Center of Boston [Kenneth Walsh] and The Johns Hopkins University School of Medicine [Gregg Semenza]
Two research collaborations
Development of gene therapy products to treat occlusive vascular disease: Fas ligand gene therapy (to inhibit vascular smooth muscle proliferation after angioplasty; Walsh) and HIF-1 gene therapy (hypoxiainducible factor-1 is expressed by cells exposed to subnormal levels of oxygen; Semenza)
For each separate agreement, Genzyme will fund research and pay option fees; scientists get access to Genzyme¿s viral and non-viral vectors; Genzyme gets exclusive option to license technology (5/98)
Genzyme Molecular Oncology
Dana-Farber Cancer Institute [Donald Kufe]
License
Use of fusion cell technology to create anticancer vaccine that stimulates immune response to tumor (dendritic cells are fused with tumor cells)
Genzyme Molecular gets option for an exclusive license to technology; Genzyme Molecular will fund research for 18 months (5/98)
GlycoDesign Inc.* (Canada)
The Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Canada)
License
Recombinant inhibitors of transforming growth factor beta (TGF-B; based on binding domain that regulates interaction of TGF-B with its ligand)
GlycoDesign licensed patents; Lunenfeld Institute gets one-time payment plus royalties (7/98)
GlycoDesign Inc.* (Canada)
National Research Council of Canada (NRC)
Research collaboration
Program to discover new antibiotics using low-molecular-weight oligosaccharides found on surface of certain bacteria
Two-year agreement initially will fund NRC¿s Institute for Biological Sciences to support cloning and expression of bacterial enzymes (10/98)
HemaSure Inc. (OTC Bulletin Board:HMSR)
The American Red Cross
Strategic alliance
Co-development of enhanced versions of HemaSure¿s leuko-eduction filters
Parties renewed alliance for 5 years, with option to extend for another 5 years (8/98)
Hoechst-Ariad Genomics Center (joint venture between Ariad Pharmaceuticals Inc. and Hoechst Marion Roussel Inc.)
Harvard School of Public Health [Arthur Lee]
Research collaboration
Identification of genes that regulate smooth muscle cell differentiation and are thus involved in atherosclerosis and angiogenesis
Hoechst-Ariad has option on exclusive license to any discoveries (7/98)
Hyseq Inc.
University of California, San Francisco (UCSF) [John Kane]
Research collaboration
Use of Hyseq¿s sequencing by hybridization technology to detect gene loci, genome mutations and polymorphisms that can be used to diagnose and treat cardiovascular diseases; creation of cardiovascular polymorphism database
This is 1st collaboration under Hyseq¿s pharmacogenomics initiatives; UCSF will collect samples from 20,000 genetically diverse individuals (many with related clinical histories); Hyseq gets exclusive right to commercialize the database and may make it available to 3rd parties (2/98)
Idun Pharmaceuticals Inc.*
Emory University [Xiaodong Wang]
License
Use of apoptosis model system (which uses extracts of normal cells) to screen for compounds that inhibit or activate apoptosis
Idun gets exclusive license to technology; further details ND (8/98)
Idun Pharmaceuticals Inc.*
Thomas Jefferson University [Emad Alnemri]
License; research collaboration
Development of caspases and other proteins that are key regulators in apoptosis (includes caspase-13, a protease; regulatory proteins FLAMES 1 and 2 and TRAIL receptors, members of tumor necrosis factor receptor family)
Idun gets exclusive license to patent applications covering certain cell death proteins; further details ND (1/98)
Igen International Inc.
The Centers for Disease Control
Cooperative Research and Development Agreement (CRADA)
Development of rapid, non-microscopic test to detect and quantify Cryptosporidium parvum parasites in drinking water and fecal samples
Igen will develop test via its Origen technology; further details ND (9/98)
Ilex Oncology Inc.
The Burnham Institute [Erkki Ruoslahti; Renata Pasqualini]
License
Development and testing of compound that links a tumorhoming peptide to chemotherapeutic drug doxorubicin (THP-dox); binds to and destroys blood vessels that nourish solid tumors and releases doxorubicin
Ilex gets license to technology; Burnham gets a warrant to buy $5M in Ilex stock at 120% premium to market; Burnham also gets milestone payments and royalties (3/98)
Imutec Pharma Inc. (TSE:IMT; Canada)
Harvard Medical School [Jose Halperin]
Research collaboration
Identification and characterization of receptor associated with anti-proliferative and anti-angiogenic activity of drug clotrimazole
Imutec will fund research; further details ND (5/98)
Imutec Pharma Inc. (TSE:IMT; Canada)
National Cancer Institute (NCI) of the National Institutes of Health
License; screening agreement
NCI will screen Imutec¿s anti-cancer compounds in its panel of cancer cell lines
NCI gets royalty-free license to compounds; further details ND (3/98)
Incyte Pharmaceuticals Inc.
Montefiori Medical Center [Leonard Augenlicht]
License
Use of defined hybridization array to analyze gene expression in diagnosis and prognosis of disease, for disease risk evaluation and to monitor effects of drugs on gene expression
Incyte gets exclusive license to technology plus sublicensing rights; further details ND (10/98)
Interneuron Pharmaceuticals Inc.
Tulane University [Akira Arimura]
License
Patent that covers two forms of the neuropeptide PACAP (pituitary adenylate cyclase activating polypeptide) and their analogues; for treating stroke and other neurodegenerative diseases
Interneuron gets exclusive worldwide rights to patent and patent applications; Interneuron will focus on developing one version of PACAP, the 38amino-acid form (PACAP38) which crosses blood-brain barrier; Interneuron will fund research for 2 years, and pay upfront licensing fee, milestones and royalties (4/98)
Introgen Therapeutics Inc.*
Imperial Cancer Research Technology Ltd. (U.K.)
License
Use of tumor-suppressor gene PTEN in cancer gene therapy; initially, in combination with Introgen¿s adenovirus-mediated gene delivery system for treating prostate and brain cancer
Introgen gets exclusive option on license; Imperial Cancer gets upfront payment; if Introgen exercises option, Imperial Cancer gets research funds, milestones and royalties (6/98)
Ligand Pharmaceuticals Inc.
The Salk Institute for Biological Studies
License
Non-peptide hormone 9-cis retinoic acid (active ingredient in Panretin Gel)
Ligand exercised its option for an exclusive license; it paid a one-time fee of $4.1M for a fully paid-up license (5/98)
Medical Science Systems Inc.
The University of North Carolina at Chapel Hill [Steven Offenbacher; James Beck; Gerardo Heiss]
Research collaboration
Additional clinical trials on utility of Medical Science System¿s genetic susceptibility test for coronary heart disease
Research program will use university¿s database on risk factors (Atherosclerosis Risk in the Community); no further details (7/98)
Megabios Corp.
University of Pittsburgh [Paul Robbins; Christopher Evans]
License; two research collaborations
Rheumatology; in vivo and ex vivo gene-based therapies for joint diseases (viral and non-viral delivery systems)
Megabios acquired patent rights and technology portfolio; Megabios issued 0.12M shares of common stock to university in exchange for exclusive license to family of patents and patent applications; Megabios established research and consulting relationships with Robbins and Evans; Megabios will fund R&D at university labs and has started in-house research programs in rheumatoid arthritis, osteoarthritis and cartilage repair (3/98)
Megabios established a collaboration and consulting relationship with Glorioso; Megabios gets certain rights to intellectual property and technology developed in the collaboration (4/98)
Micrologix Biotech Inc. (Canada)
The Protein Engineering Network Centres of Excellence (PENCE; Canada) [Robert Hodges; Randall Irvin]
License; research collaboration
Co-development of diagnostics and therapeutics based on synthetic analogues of family of natural antimicrobial peptides
4-year agreement; US$1.27M will be invested in program (50% by Micrologix, 50% by Canadian National Centres of Excellence); Micrologix gets exclusive worldwide license to technology for use in human and veterinary health care and in agriculture (2/98)
Millennium Biotherapeutics Inc. (Majority-owned subsidiary of Millenium Pharmaceuticals Inc.)
Harvard Medical School
Material transfer agreement
Sharing of novel genes and biological materials
Agreement making it easier for scientists across the six HMS basic science departments to study MBio products, and to establish funded research partnerships (12/98)
Millennium Pharmaceuticals Inc.
The University of Texas M.D. Anderson Cancer Center [Robert Bast; Gabriel Hortobagyi; Jordan Gutterman; Waun-Ki Hong; Gordon Mills]
Clinical collaboration
Use of Millennium¿s genomics technologies to identify gene targets and markers for prognosis, diagnosis and therapy of cancer; also, correlation of gene expression patterns with chemotherapy sensitivity/resistance
3-year collaboration in 2 phases; 1st phase focuses on collecting oncologic data from existing clinical samples and tissue collections; in 2nd phase, Millenium will help fund specific research programs and provide limited access to its technologies in exchange for certain rights to inventions and discoveries (8/98)
Millennium Pharmaceuticals Inc.
The University of Pittsburgh [Rajiv Dhir]
Clinical collaboration
Use of Millennium¿s genomics technologies to identify gene targets and markers for prognosis, diagnosis and therapy of major diseases
3-year collaboration; Millennium gets access to Western Pennsylvania Genitourinary Tissue Bank for identification of disease targets; Millennium will provide financial support, opportunities for collaborative research programs and limited access to its technologies in exchange for certain rights to inventions and discoveries (8/98)
Millennium Pharmaceuticals Inc.
Mayo Clinic
Research collaboration
Identification and characterization of novel gene targets and markers in several disease areas, initially cancer
Five-year alliance focused on using targets and markers for diagnosis, prognosis and treatment (11/98)
MitoKor Inc.*
The University of California, San Francisco [Brad Gibson; Martin Shetlar]
Research collaboration
Mitochondrial and nuclear genomics and proteomics research in Alzheimer¿s disease; use of mass spectrometry to study consequences of metabolic dysfunction and oxidative stress
Partnership established through the Biotechnology Strategic Targets for Alliances in Research Project (BioSTAR) (6/98)
Molecular Dynamics Inc. and Amersham Pharmacia Biotech (Sweden)
University of Washington [Leroy Hood]
Research collaboration
DNA microarray technology access agreement; for continued development of high-throughput microarray system (which compares levels of gene expression in normal and diseased cells)
University will provide technical expertise while gaining early access to integrated microarray systems; companies will provide microarray fabrication, hybridization and optical scanning instrumentation and software as well as matched reagents and consumables (1/98)
Myriad Genetics Inc. NABI
Rockefeller University Centers for Disease Control and Prevention (U.S. Public Health Service)
License Cooperative Research and Development Agreement (CRADA)
Certain genes (not described) involved in control of cancer cell growth Determination of efficacy of NabiCivacir (human polyclonal antibody to hepatitis C virus; HCV) for preventing or modifying HCV infection in experimentally infected chimpanzees
Myriad gets exclusive worldwide license on genes and rights to all therapeutic and diagnostic applications (4/98) ND (4/98)
NABI
University of Maryland [Ramachandra Hosmane]
License
Ring expanded nucleoside (RENs) and nucleotide (RENt) technology; chemically synthesized analogues with anti-viral, anti-microbial and anti-tumor activity
NABI gets exclusive worldwide rights to make, use and sell products based on technology (5/98)
Neoprobe Corp.
Children¿s Cancer Group
Development collaboration
They agreed to collaborate to gain regulatory clearance for radiolabeled drug 125I-MIBG for intraoperative detection of neuroblastoma
Neoprobe licensed rights from CIS-US Inc., and agreed in principle to develop with CCG; further terms ND (12/98)
Neurotech SA* (France)
Kennedy Krieger Institute [John Laterra]
Research collaboration
Development of endothelial-cell-based gene therapies for treating glioblastoma (targeted delivery of antitumoral peptides)
ND (3/98)
NeXstar Pharmaceuticals Inc.
University of California at Berkeley [James Allison]
License
CTLA-4 Blockade technology for use as therapeutic vaccine for cancer (may be able to stimulate immune system to block tumor growth)
NeXstar gets exclusive option to license technology; further details ND (5/98)
Oncor Inc.
Yale University [Paul Lizardi]
License
Rolling circle amplification technology (RCAT; isothermic nucleic acid amplification system) for use in diagnostics for cancer, infectious diseases, molecular genotyping, pharmacogenetics
Oncor exercised option from 1996 agreement to license RCAT and obtained certain rights to technology; Oncor also will participate in limited liability company together with Yale University and Molecular Staging Inc. to commercialize RCAT through sublicenses (3/98)
OraPharma Inc.*
The University of North Carolina at Chapel Hill [Ray Williams; Steven Offenbacher]
Research collaboration
Treatments and diagnostics for oral diseases, especially periodontal disease
OraPharma gets option on exclusive worldwide license to all technology resulting from program (9/98)
Origen Therapeutics Inc.*
North Carolina State University [James Petitte]
License
Avian embryonic stem cell technologies to enable genetic engineering of poultry; goal to produce recombinant human protein therapeutics in chicken eggs
Origen gets exclusive license to broad technology platform for all applications (1/98)
OSI Pharmaceuticals Inc.
Vanderbilt University Diabetes Center
Research collaboration
Small-molecule drugs for treating Type II diabetes; initial focus on 4 targets, including hexokinase II and other gene expression targets
Collaboration ranges from drug discovery and development to early clinical testing; further details ND (4/98)
Osiris Therapeutics Inc.*
The Institute for Cancer Research at the University of Genoa (Italy) [Ranieri Cancedda]
Research collaboration
Role of mesenchymal stem cells (MSC) and other stromal progenitor cells in regenerating tissues following damage due to cancer chemotherapy/radiation, orthopedic injuries and other connective tissue disorders
3-year agreement; Osiris will provide $1M in research funds in exchange for exclusive worldwide rights to technology (3/98)
Pacific Pharmaceuticals Inc. (OTC Bulletin Board:PPHA)
The National Cancer Institute (NCI) of the National Institutes of Health
Cooperative Research and Development Agreement
Further clinical development of company¿s chemosensitizing agent O6 benzylguanine
Parties will jointly develop clinical plan, including certain studies to be funded and conducted by NCI; company retains right to conduct independent clinical studies (8/98)
Pacific Pharmaceuticals Inc. (OTC Bulletin Board:PPHA)
Pennsylvania State University [Anthony Pegg]
License
O6 benzylguanine, series of compounds that enhance antitumor activity of chemotherapeutic agents known as O6 alkylators (inactivates a DNA repair enzyme)
Pacific Pharmaceuticals gets exclusive worldwide license in exchange for license fees, milestones (to be paid in cash or stock) and royalties; Paramount Capital LLC acted as financial advisor to Pacific Pharmaceuticals (3/98)
Paracelsian Inc.
The Southern Research Institute [Robert Struck]
Research collaboration
Animal experiments to determine anti-tumor activity of series of traditional Chinese medicine herbal extracts
Southern Research will test compounds in mice; if successful, parties will collaborate on isolation of key compounds and seek R&D funds (7/98)
PathoGenesis Corp.
The Cystic Fibrosis Foundation
Product rights
TOBI (tobramycin solution for inhalation) for managing cystic fibrosis patients with Pseudomonas aeruginosa
PathoGenesis acquired all rights to product and will make payments to foundation over next 2 years (6/98)
PPL Therappeutics plc (Scotland)
The Roslin Institute (Scotland)
License
Nuclear transfer technology for nutraceutical and therapeutic protein production in milk of livestock and rabbits
PPL licensed exclusive worldwide rights to technology (6/98)
Ribi ImmunoChem Research Inc.
The University of Nebraska [Sam Sanderson]
License
Molecular adjuvant technology for use in immunotherapy of cancer and infectious diseases; involves class of synthetic peptides that bind to complement receptors
Ribi gets exclusive worldwide license to technology (6/98)
Ribozyme Pharmaceuticals Inc.
Duke University [Bruce Sullenger]
License
Use of ribozymes to repair genetic defect in beta-globin gene; for treating sickle-cell anemia
Ribozyme gets exclusive worldwide license to technology (6/98)
SARCO Inc. (wholly owned subsidiary of Pharmaceutical Product Development Inc.)
Duke University Medical Center [Patrick Casey]
Research collaboration
Small-molecule compounds that inhibit geranyl geranyl and farnesyl farnesyl transferases; for treating cancer
SARCO will use its combinatorial chemistry to generate and refine compound libraries for further study at Duke; Sarco will sponsor research and has option to obtain exclusive license on any inventions (5/98)
Select Therapeutics Inc. (OTC Bulletin Board:SLPU)
Institut Curie and The Centre National de la Recherche Scientifique (France)
Research collaboration
Methods for targeting dendritic cells for stimulating immune response; technology based on expression of receptor for verotoxin (naturally occurring protein produced by strains of Escherichia coli that binds to receptors on certain tumor types)
Select Therapeutics will fund research and gets option for exclusive worldwide license to technology (6/98)
Select Therapeutics Inc. (OTC Bulletin Board: SLPU)
Ontario Cancer Institute (Canada) [Jean Garlepy] and University of Toronto Innovation Foundation
License; research collaboration
Use of shiga-like toxin 1 (SLT-1) as agent to selectively kill cancer cells in bone marrow prior to autologous stem cell transplants in cancer patients
Select Therapeutics gets exclusive worldwide rights to invention in return for research support and royalty payments (2/98)
Select Therapeutics Inc. (OTC Bulletin Board: SLPU)
Toronto Hospital for Sick Children (Canada)
License; research collaboration
Antibiotic therapies; drugs that have been chemically modified to alter binding to and killing of bacterial pathogens
Select Therapeutics will develop program for synthesis and testing of new antibiotics; further details ND (3/98)
Selective Genetics Inc.*
The University of Michigan [Jeffrey Bonadio; Steven Goldstein]
License
Use of gene-activated matrix technology to transfer genes into bone progenitor cells and tissue repair sites
Selective Genetics gets exclusive license to technology (7/98)
Sheffield Pharmaceuticals Inc.
University of Michigan [Luis Bernal]
Collaborative agreement
Use of university technology to optimize Sheffield¿s pulmonary delivery systems
University will assist Sheffield in optimizing aerodynamic properties of aerosols; terms ND (12/98)
Siga Pharmaceuticals Inc.
The Ludwig Institute for Cancer Research
Research collaboration
Immunotherapeutic vaccines for melanoma, breast, bladder and ovarian cancer; combination of Siga¿s vaccine delivery system with Ludwig Institute¿s tumor antigens
Parties will jointly own any technology developed in collaboration (9/98)
Siga Pharmaceuticals Inc.
U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
Cooperative Research and Development Agreement
Development of vaccine against staphylococcal infections.
Project combining Siga¿s delivery system with proprietary USAMRIID antigen to develop vaccine. (11/98)
Small Molecule Therapeutics Inc.*
State University of New York at Stony Brook
Sponsored research agreement; license
Development and use of cell-based functional screen to identify signaling proteins in nuclear factor kappa-B (NF-kB) activation pathway
Small Molecule Therapeutics will fund research in exchange for option on exclusive license to any targets discovered (6/98)
StressGen Biotechnologies Corp. (Canada)
University of Miami [Richard Voellmy]
License
Heat shock transcription factors (HSF), molecules that regulate production of stress proteins; to protect cells from damage caused by ischemia/ reperfusion and by inflammatory reactions
StressGen licensed family of international patent applications broadly covering mutated forms of HSFs; company will develop screening assays for small molecule drugs that either up-or down-regulate production of stress proteins (2/98)
StressGen Biotechnologies Corp. (Canada)
The University of Miami; The University of Connecticut; Hartford Hospital
Research collaboration
Identification and optimization of small molecules that modulate cellular production of stress proteins; to promote cell survival under conditions that cause tissue damage
Multi-institution collaboration based on StressGen¿s 2/98 exclusive license for University of Miami¿s discovery platform of heat shock transcription factors (7/98)
Sugen Inc.
Cancer Research Campaign (CRC; UK)
Clinical collaboration
Conducting Phase I trial of Sugen¿s cancer drug, SU6668, in patients with advanced malignancies
Trial will be condcuted in association with CRC (11/98)
Synsorb Biotech Inc. (Canada)
University of Alberta [Ole Hindsgaul; David Schriemer]
License
High-throughput screening technology that determines if compounds have agonist or antagonist activity
Synsorb licensed technology and has formed new subsidiary to develop it; Synsorb will screen its own carbo-hybrid library but will make technology available to other companies (5/98)
T Cell Sciences Inc.
Walter Reed Army Institute of Research (WRAIR)
Cooperative Research and Development Agreement (CRADA)
Combination of T Cell¿s complement inhibition technology with WRAIR¿s liposome drug delivery system to develop hemoglobin-containing liposomes as emergency blood substitute
5-year agreement; this expands on earlier CRADA that tested TP10¿s ability to inhibit complement activation by liposome-encapsulated hemoglobin; under the new CRADA, T Cell has exclusive rights to license all discoveries (1/98)
Targeted Genetics Corp.
National Heart, Lung and Blood Institute (NHLBI) of the National Institutes of Health
Research collaboration
Use of recombinant adeno-associated viral (rAAV) vectors as well as non-viral gene delivery vehicles for targeted gene transfer to liver tissue and other tissues in vivo
Targeted Genetics will provide its rAAV vector and other nonviral vectors to NHLBI; further details ND (3/98)
Therion Biologics Corp.*
The Ludwig Institute for Cancer Research
License
Use of Ludwig Institute¿s human tumor antigen NY-ESO-1 with Therion¿s pox virus vectors to create immunotherapeutics for various cancers
Therion will develop live recombinant pox virus vectors that incorporate ESO-1 gene; Therion gets exclusive option to license gene for this use; Ludwig Institute will conduct 1st clinical trials (9/98)
Tranzyme Inc.*
University of Alabama (UAB) Research Foundation
License
Series of patents on lentivirus vectors for gene therapy; also, diagnostic assay for HIV drug sensitivity
Tranzyme gets exclusive license to patents (9/98)
Trega Biosciences Inc.
Torrey Pines Institute for Molecular Studies [Richard Houghten]
Discontinuation of research agreement
Design and synthesis of small-molecule combinatorial libraries
Agreement dates from 1992 and was extended in 5/97 for 12 months; parties agreed to terminate agreement because of divergence of respective research goals (1/98)
Tripos Inc.
The Scripps Research Institute [Jeffrey Skolnick; Adam Godzik]
Research collaboration
Development of bioinformatics software applications for drug discovery; includes new MatchMaker II software for 3D modeling of protein structures
2-year consulting and collaboration agreement; Tripos gets exclusive distribution rights for software (4/98)
Tropix (Perkin-Elmer subsidiary)
Stanford University (Helen Blau)
License
Technology for analyzing protein-protein interactions.
Tropix gets exclusive rights to perform assay services using the technology. (12/98)
UroGenesys Inc.*
University of California Los Angeles [Robert Reiter]
License
Prostate stem cell antigen gene (up-regulated only in prostate cancer)
UroGenesys gets exclusive worldwide rights to gene; details ND (2/98)
U.S. Bioscience Inc.
National Cancer Institute of the National Institutes of Health (NIH) [Robert Yarchoan]
Cooperative Research and Development Agreement (CRADA)
Clinical development of lodenosine (formerly FddA; purine-based reverse transcriptase inhibitor) for treating HIV infection and AIDS
U.S. Bioscience already has an exclusive worldwide license to compound; NIH is conducting Phase I trials in adult and pediatric patients; U.S. Bioscience will continue clinical development and seek regulatory approval (1/98)
Vaxcel Inc. (OTC Bulletin Board:VXCL)
University College London (U.K.)
License
Genetically engineered and mutated beta-human chorionic gonadotropin proteins for use as immunogens in therapeutic cancer vaccines (combined with Vaxcel¿s Optivax copolymer adjuvant technology)
Vaxel gets exclusive worldwide rights to technology; further details ND (3/98)
VaxGen Inc.*
The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health
Research collaboration
Research on immune responses induced by preventive AIDS vaccine AIDSVAX (recombinant gp120-based vaccine; currently in North American Phase III trials); also research on use of AIDSVAX in combination with other vaccines being studied by NIAID
ND (8/98)
Vimrx Pharmaceuticals Inc.
Columbia University
Formation of joint venture Ventiv Biogroup
Drug discovery and development company focused on receptor target involved in diabetic complications (RAGE; receptor for advanced glycation end-products)
Parties transformed former joint venture Vimrx Genomics Inc. (gene discovery; formed 3/97) into Ventiv Biogroup; Ventiv gets gene discoveries already licensed by Columbia to Vimrx Genomics, plus 3 Vimrx Pharmaceuticals development programs; Ventiv is 90% owned by Vimrx Pharmaceuticals and 10% owned by Coumbia; Ventiv acquired rights to RAGE from Columbia, in exchange for which it will pay $2M-$3M/year for 3 years in research support, plus milestones and royalties; VIMRx Genomics¿ gene discovery collaboration with Columbia (from 11/97) will cease along with $30M in funding; Ventiv retains options to certain future gene discoveries in exchange for $5.5M in funding over 4 years (3/98)
Vion Pharmaceuticals Inc.
Yale University [Alan Sartorelli; John Pawelek]
Expansion of two research collaborations
Anticancer compounds (including Promycin, currently in Phase III trials for head and neck cancer) that selectively target hypoxic cancer cells (Sartorelli); TAPET technology (tumor amplified protein expression therapy) which uses engineered bacteria to target anticancer therapy to solid tumors (Pawelek)
Vion expanded collaborations with both labs; Sartorelli gets $0.6M over 3 years to support research; Pawalek gets $2.56M over 3 years to support research (5/98)
Viragen Inc.
German Red Cross blood banks (Germany)
Supply agreement
White blood cells to be used in making Viragen¿s 2nd generation multispecies natural alpha interferon Omniferon
Long-term agreement; Viragen has preferential access to 100% of human white blood cells collected by blood banks (3/98)
Viragen Inc.
Netherlands blood banks (the Netherlands)
Supply agreement
White blood cells to be used in making Viragen¿s 2nd generation multispecies natural alpha interferon Omniferon
Preliminary agreement to form long-term exclusive supply agreement; parties also will develop a natural interferon treatment program for the Netherlands; specific terms ND (2/98)
Viragen Inc. and its wholly owned subsidiary Viragen USA Inc.
America¿s Blood Centers
Strategic alliance
Supply of usable human leukocytes for manufacturing of Omniferon (alpha-interferon)
Viragen gets preferential access to 100% of leukocyte supply for a minimum of 10 years; Blood Center and its members have option of buying 13.6% of Viragen USA¿s common stock on achievement of milestones (7/98)
Viragen Inc. and its wholly owned subsidiary Viragen USA Inc.
The American Red Cross
Supply agreement
Supply of human leukocytes for production of Omniferon (alpha interferon) and LeukoVax
Long-term supply agreement for up to 15 years; further details ND (9/98)
Virus Research Institute Inc.
Harvard University
License
Immunotherapy delivery system Therapore (consists of 2 bacterial proteins that transport polypeptides into cells to induce cell-mediated immune responses)
Virus Research Institute gets exclusive worldwide license; further details ND (1/98)
Vysis Inc.
University Hospital of Vrije Universiteit at Amsterdam (the Netherlands)
Research collaboration
Use of Vysis¿ DNA probe technology to develop fetal-cell identification markers (to detect genetic abnormalities in fetal cells present in maternal circulation)
Vysis gets exclusive rights to commercialize fetal-cell markers as part of its noninvasive prenatal test; terms ND (4/98)
Wisconsin Genetics Inc. (subsidiary of Endorex Corp.)
The University of Wisconsin-Madison
Research collaboration
Preclinical development of monoterpenes (plant-derived compounds) as anticancer drugs
ND (7/30)
Xenova Discovery Ltd. (subsidiary of Xenova Group plc (U.K.)
The Institute of Grassland and Environmental Research (Wales)
Strategic alliance
Establishment of phytochemistry group that will apply Xenova¿s microbial drug discovery techniques to search for bioactive compounds from European and tropical plants
ND (1/98)
ZymeTx Inc. (NASDAQ: ZMTX)
Oklahoma Medical Research Foundation
License
Family of compounds for treating HIV infection; lead compound ZX-0851 believed to act by modifying HIV RNA
ZymeTx acquired worldwide rights to compounds (7/98)
See subscription options